Secondary Objectives of Part 1 (Dose Escalation Phase):~Characterize the pharmacokinetic (PK) profile of SKL27969~Evaluate the preliminary anti-tumor activity of SKL27969~Secondary Objectives of Part 2 (Dose Expansion Phase):~Investigate the safety and tolerability of SKL27969 at the RP2D in patients with selected tumor types~Characterize the PK of SKL27969
Primary Objective of Part 1 (Dose Escalation Phase): Evaluate the safety and tolerability of SKL27969, and determine the maximum tolerated dose (MTD) and/or recommended Phase 2 dose (RP2D) of SKL27969~Primary Objective of Part 2 (Dose Expansion Phase): Evaluate the preliminary anti-tumor activity of SKL27969